Editorial update — September 11, 2026: The original announcement used broad promotional language and presented retrospective proof-of-concept findings as though they established commercial screening performance. Those statements have been withdrawn.
The historical update concerned miRoncol's research into blood-based microRNA patterns and machine-learning models associated with multiple cancer types. The 2024 Nobel Prize in Physiology or Medicine recognized the discovery of microRNA and its role in gene regulation; it did not evaluate or endorse miRoncol, miCheckup or any product.
Published research used retrospective case-control datasets. The 2024 paper reported greater than 99% specificity and greater than 90% sensitivity for the majority of evaluated cancer types in its study dataset, with material variation by cancer type. These figures do not establish prospective population-screening performance or predict an individual result.
Additional prospective validation and clinical evaluation are needed to establish real-world screening performance and clinical utility. The research does not establish that use of the current service improves survival, reduces healthcare costs or replaces recommended screening or diagnostic care.